Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics demonstrates a strategic focus on financial prudence by executing a workforce reduction and reallocating resources toward the development of EO-1022, a HER3-targeting antibody-drug conjugate, which may enhance future growth potential. The company aims to streamline operations and conserve funds in response to challenging market conditions, reflecting a disciplined financial approach. Moreover, the adjustments made to financial models, including a planned revenue recognition for EO-1022 starting in 2031, highlight a forward-looking strategy that positions the company for long-term success while navigating its clinical-stage landscape.

Bears say

Enliven Therapeutics has faced a significant setback with the discontinuation of the Claudin 18.2-targeting ADC, EO-3021, due to lower-than-expected efficacy in its Phase 1 study, raising concerns about the viability of this asset within its pipeline. Despite the treatment's tolerable safety profile, the reduced efficacy diminishes its attractiveness for further investment, leading to skepticism about the company's growth potential. Additionally, the drastic reduction in the 12-month price target from $6.00 to $1.00 reflects a lack of confidence in Enliven's ability to deliver successful product candidates and generate substantial returns in the near future.

ELVN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELVN has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.